NOVOCURE LTD, 10-Q filed on 11/2/2016
Quarterly Report
Document and Entity Information
9 Months Ended
Sep. 30, 2016
Oct. 27, 2016
Document Document And Entity Information [Abstract]
 
 
Document Type
10-Q 
 
Amendment Flag
false 
 
Document Period End Date
Sep. 30, 2016 
 
Document Fiscal Year Focus
2016 
 
Document Fiscal Period Focus
Q3 
 
Trading Symbol
NVCR 
 
Entity Registrant Name
Novocure Ltd 
 
Entity Central Index Key
0001645113 
 
Current Fiscal Year End Date
--12-31 
 
Entity Filer Category
Non-accelerated Filer 
 
Entity Common Stock, Shares Outstanding
 
86,780,413 
CONDENSED INTERIM CONSOLIDATED BALANCE SHEETS (USD $)
In Thousands, unless otherwise specified
Sep. 30, 2016
Dec. 31, 2015
CURRENT ASSETS:
 
 
Cash and cash equivalents
$ 115,822 
$ 119,423 
Short-term investments
119,724 
150,001 
Restricted cash
72 
87 
Receivables and prepaid expenses
11,840 
10,799 
Inventories
23,972 
13,594 
Total current assets
271,430 
293,904 
LONG-TERM ASSETS:
 
 
Property and equipment, net
9,886 
6,552 
Field equipment, net
8,042 
6,029 
Severance pay fund
89 
79 
Other long-term assets
1,646 
772 
Total long-term assets
19,663 
13,432 
TOTAL ASSETS
291,093 
307,336 
CURRENT LIABILITIES:
 
 
Trade payables
15,243 
16,755 
Other payables and accrued expenses
14,469 
11,872 
Total current liabilities
29,712 
28,627 
LONG-TERM LIABILITIES:
 
 
Long-term loan, net of discount and issuance costs
95,970 
23,097 
Employee benefit liabilities
3,132 
2,057 
Other long-term liabilities
4,036 
2,735 
Total long-term liabilities
103,138 
27,889 
TOTAL LIABILITIES
132,850 
56,516 
COMMITMENTS AND CONTINGENCIES
SHAREHOLDERS' EQUITY:
 
 
Ordinary shares no par value, unlimited shares authorized; issued and outstanding: 85,775,203 (unaudited) shares and 83,778,581 shares at September 30, 2016 and December 31, 2015, respectively
Additional paid-in capital
658,086 
640,406 
Accumulated other comprehensive loss
(2,085)
(1,505)
Accumulated deficit
(497,758)
(388,081)
Total shareholders' equity
158,243 
250,820 
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY
$ 291,093 
$ 307,336 
CONDENSED INTERIM CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)
9 Months Ended 12 Months Ended
Sep. 30, 2016
Dec. 31, 2015
Statement Of Financial Position [Abstract]
 
 
Common stock, par value
$ 0 
$ 0 
Common stock, shares authorized
Unlimited 
Unlimited 
Common stock, shares issued
85,775,203 
83,778,581 
Common stock, shares outstanding
85,775,203 
83,778,581 
CONDENSED INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)
In Thousands, except Share data, unless otherwise specified
3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Dec. 31, 2015
Income Statement [Abstract]
 
 
 
 
 
Net revenues
$ 21,674 
$ 8,953 
$ 52,646 
$ 20,704 
$ 33,087 
Cost of revenues
11,118 
5,659 
28,897 
14,306 
20,610 
Impairment of field equipment
 
 
6,412 
 
 
Gross profit
10,556 
3,294 
17,337 
6,398 
12,477 
Operating costs and expenses:
 
 
 
 
 
Research, development and clinical trials
10,233 
10,211 
32,996 
32,903 
43,748 
Sales and marketing
15,865 
8,916 
43,771 
24,137 
38,861 
General and administrative
12,723 
8,405 
38,010 
22,748 
33,864 
Total operating costs and expenses
38,821 
27,532 
114,777 
79,788 
116,473 
Operating loss
(28,265)
(24,238)
(97,440)
(73,390)
(103,996)
Financial expenses, net
2,189 
809 
3,293 
2,277 
3,151 
Loss before income tax expense
(30,454)
(25,047)
(100,733)
(75,667)
(107,147)
Income tax expense
3,174 
976 
8,944 
2,986 
4,434 
Net loss
$ (33,628)
$ (26,023)
$ (109,677)
$ (78,653)
$ (111,581)
Basic and diluted net loss per ordinary share
$ (0.39)
$ (2.09)
$ (1.29)
$ (6.21)
$ (3.67)
Weighted average number of ordinary shares used in computing basic and diluted net loss per share
85,774,874 
12,431,586 
85,153,644 
12,666,455 
30,401,603 
CONSOLIDATED INTERIM STATEMENTS OF COMPREHENSIVE INCOME (USD $)
In Thousands, unless otherwise specified
3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Dec. 31, 2015
Statement Of Income And Comprehensive Income [Abstract]
 
 
 
 
 
Net loss
$ (33,628)
$ (26,023)
$ (109,677)
$ (78,653)
$ (111,581)
Other comprehensive loss, net of tax :
 
 
 
 
 
Change in foreign currency translation adjustments
 
64 
 
 
Pension benefit plan
(409)
 
(644)
 
(1,505)
Total comprehensive loss
$ (34,029)
$ (26,023)
$ (110,257)
$ (78,653)
$ (113,086)
CONDENSED INTERIM STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (USD $)
In Thousands, except Share data
Total
USD ($)
Over-Allotment
USD ($)
Series J Preferred Stock
USD ($)
Ordinary Shares
Ordinary Shares
Over-Allotment
Preferred Shares
Preferred Shares
Series J Preferred Stock
Additional Paid-in Capital
USD ($)
Additional Paid-in Capital
Over-Allotment
USD ($)
Additional Paid-in Capital
Series J Preferred Stock
USD ($)
Accumulated Other Comprehensive Loss
USD ($)
Accumulated Deficit
USD ($)
Balance at Dec. 31, 2014
$ 97,875 
 
 
 
 
 
 
$ 374,375 
 
 
 
$ (276,500)
Balance (in shares) at Dec. 31, 2014
 
 
 
13,431,414 
 
58,676,017 
 
 
 
 
 
 
Share-based compensation to employees
11,860 
 
 
 
 
 
 
11,860 
 
 
 
 
Exercise of options and warrants
2,038 
 
 
 
 
 
 
2,038 
 
 
 
 
Exercise of options and warrants (in shares)
 
 
 
731,665 
 
 
 
 
 
 
 
 
Issuance of shares, net
 
157,534 1
94,599 2
 
 
 
 
 
157,534 1
94,599 2
 
 
Issuance of shares, net (in shares)
 
 
 
 
7,876,195 
 
4,068,500 
 
 
 
 
 
Issuance of shares and options in respect of settlement, net of fair value of shares provided as indemnification (in shares)
 
 
 
(1,005,210)
 
 
 
 
 
 
 
 
Conversion of preferred shares to ordinary shares
 
 
 
62,744,517 
 
(62,744,517)
 
 
 
 
 
 
Other comprehensive loss, net of tax benefit
(1,505)
 
 
 
 
 
 
 
 
 
(1,505)
 
Net loss
(111,581)
 
 
 
 
 
 
 
 
 
 
(111,581)
Balance at Dec. 31, 2015
250,820 
 
 
 
 
 
 
640,406 
 
 
(1,505)
(388,081)
Balance (in shares) at Dec. 31, 2015
 
 
 
83,778,581 
 
 
 
 
 
 
 
 
Share-based compensation to employees
16,719 
 
 
 
 
 
 
16,719 
 
 
 
 
Exercise of options and warrants
961 
 
 
 
 
 
 
961 
 
 
 
 
Exercise of options and warrants (in shares)
 
 
 
1,996,622 
 
 
 
 
 
 
 
 
Other comprehensive loss, net of tax benefit
(580)
 
 
 
 
 
 
 
 
 
(580)
 
Net loss
(109,677)
 
 
 
 
 
 
 
 
 
 
(109,677)
Balance at Sep. 30, 2016
$ 158,243 
 
 
 
 
 
 
$ 658,086 
 
 
$ (2,085)
$ (497,758)
Balance (in shares) at Sep. 30, 2016
 
 
 
85,775,203 
 
 
 
 
 
 
 
 
CONDENSED INTERIM STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY(Parenthetical) (USD $)
In Thousands, unless otherwise specified
9 Months Ended
Sep. 30, 2016
Series J Preferred Stock
 
Share issuance expenses
$ 319 
Over-Allotment
 
Share issuance expenses
$ 15,742 
CONDENSED INTERIM CONSOLIDATED CASH FLOWS (USD $)
In Thousands, unless otherwise specified
3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Dec. 31, 2015
Cash flows from operating activities:
 
 
 
 
 
Net loss
$ (33,628)
$ (26,023)
$ (109,677)
$ (78,653)
$ (111,581)
Adjustments to reconcile net loss to net cash used in operating activities:
 
 
 
 
 
Depreciation and amortization
1,553 
893 
4,063 
2,005 
3,153 
Asset write-downs and impairment of field equipment
10 
 
6,440 
42 
46 
Increase (decrease) in accrued interest expense
222 
(565)
222 
154 
672 
Share-based compensation to employees
5,626 
2,928 
16,719 
7,372 
11,860 
Amortization of discount
81 
88 
25 
231 
329 
Decrease (increase) in receivables and prepaid expenses
694 
(1,427)
(1,514)
(4,453)
(5,088)
Increase in inventories
(2,757)
(2,556)
(10,378)
(7,703)
(10,148)
Decrease (increase) in other long-term assets
(526)
250 
(804)
79 
(381)
Increase (decrease) in trade payables
(6,765)
1,512 
(2,621)
4,597 
6,961 
Increase in other payables and accrued expenses
1,651 
2,374 
2,407 
2,892 
3,579 
Increase (decrease) in employee benefit liabilities, net
80 
(10)
350 
(3)
133 
Increase (decrease) in other long-term liabilities
263 
430 
901 
(323)
581 
Net cash used in operating activities
(33,496)
(22,106)
(93,867)
(73,763)
(99,884)
Cash flows from investing activities:
 
 
 
 
 
Purchase of property and equipment
(1,715)
(1,196)
(5,055)
(3,613)
(4,667)
Purchase of field equipment
(3,113)
(1,367)
(9,213)
(3,547)
(5,604)
Decrease (increase) in restricted cash
27 
(72)
15 
(105)
(26)
Proceeds from maturity of short-term investments
120,000 
30,000 
270,000 
77,000 
104,000 
Purchase of short-term investments
(119,613)
 
(239,341)
(58,992)
(208,998)
Net cash provided by (used in) investing activities
(4,414)
27,365 
16,406 
10,743 
(115,295)
Cash flows from financing activities:
 
 
 
 
 
Proceeds from issuance of shares, net
 
 
 
94,599 
252,133 
Proceeds from long-term loan, net
72,870 
 
72,887 
22,886 
22,886 
Deferred IPO costs
 
(1,439)
 
(1,733)
 
Repayment of other long-term loan
(17)
(16)
(52)
(47)
(63)
Purchase of shares in respect of settlement
 
 
 
(5)
(5)
Exercise of options and warrants
 
12 
961 
31 
2,038 
Net cash provided by (used in) financing activities
72,853 
(1,443)
73,796 
115,731 
276,989 
Effect of exchange rate changes on cash and cash equivalents
 
64 
 
 
Increase (decrease) in cash and cash equivalents
34,951 
3,816 
(3,601)
52,711 
61,810 
Cash and cash equivalents at the beginning of the period
80,871 
106,508 
119,423 
57,613 
57,613 
Cash and cash equivalents at the end of the period
115,822 
110,324 
115,822 
110,324 
119,423 
Cash paid during the period for:
 
 
 
 
 
Income taxes
4,624 
658 
7,793 
1,683 
1,489 
Interest
$ 1,880 
$ 1,252 
$ 3,813 
$ 823 
$ 1,688 
Organization and Basis of Presentation
Organization and Basis of Presentation

NOTE 1: ORGANIZATION AND BASIS OF PRESENTATION

Organization.  NovoCure Limited (including its consolidated subsidiaries, the “Company”) was incorporated in the Bailiwick of Jersey and is principally engaged in the development, manufacture and commercialization of TTFields for the treatment of solid tumors. Since inception, the Company has devoted substantially all of its efforts to developing and commercializing a family of products to deliver TTFields for a variety of solid tumor indications, raising capital and recruiting personnel. The Company has regulatory approvals and clearances in certain countries for Optune, its first TTFields delivery system, to treat glioblastoma (“GBM”). The Company commenced marketing Optune in the United States at the end of 2011, in certain countries in Europe in 2014 and in Japan in 2015.

Financial statement preparation. The accompanying condensed consolidated financial statements include the accounts of the Company and its consolidated subsidiaries, and intercompany accounts and transactions have been eliminated. In the opinion of the Company’s management, the condensed consolidated financial statements reflect all adjustments, which are normal and recurring in nature, necessary for fair financial statement presentation. The preparation of these condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles (“GAAP”) requires management to make estimates and assumptions that affect the amounts reported in these condensed consolidated financial statements and accompanying notes. Actual results could differ materially from those estimates. These condensed consolidated financial statements and accompanying notes should be read in conjunction with the Company’s annual consolidated financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2015 (the “2015 10-K”) filed with the Securities and Exchange Commission (the “SEC”) on March 1, 2016.

The significant accounting policies applied in the audited annual consolidated financial statements of the Company as disclosed in the 2015 10-K are applied consistently in these unaudited interim consolidated financial statements.

Recently Issued Accounting Pronouncements. In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-02-Leases (ASC 842), which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e. lessees and lessors). The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight line basis over the term of the lease, respectively. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than twelve months regardless of their classification. Leases with a term of twelve months or less will be accounted for similar to existing guidance for operating leases. The new standard requires lessors to account for leases using an approach that is substantially equivalent to existing guidance for sales-type leases, direct financing leases and operating leases. ASC 842 supersedes the previous leases standard, ASC 840. The standard is effective on January 1, 2019, with early adoption permitted. The Company is currently evaluating the impact of the adoption of this standard on its consolidated financial statements.

In March 2016, FASB issued ASU 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The amendments in ASU 2016-09 affect all entities that issue share-based payment awards to their employees and involve multiple aspects of the accounting for share-based payment transactions, including income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. ASU 2016-09 is effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. Early adoption is permitted in any interim or annual period. The Company is currently evaluating the impact of the adoption of this standard on its consolidated financial statements.

In April 2016, FASB issued ASU 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing. ASU 2016-10 covers two specific topics: performance obligations and licensing. This amendment includes guidance on immaterial promised goods or services, shipping or handling activities, separately identifiable performance obligations, functional or symbolic intellectual property licenses, sales-based and usage-based royalties, license restrictions (time, use, geographical) and licensing renewals. In addition, in May 2016, FASB issued ASU No. 2016-12, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients, which is intended to not change the core principle of the guidance in Topic 606, but rather affect only the narrow aspects of Topic 606 by reducing the potential for diversity in practice at initial application and by reducing the cost and complexity of applying Topic 606 both at transition and on an ongoing basis. The Company is currently evaluating the impact of the adoption of both revenue standards on its consolidated financial statements.

In June 2016, FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. ASU 2016-13 amends the impairment model to utilize an expected loss methodology in place of the currently used incurred loss methodology, which will result in the more timely recognition of losses. ASU 2016-13 also applies to employee benefit plan accounting, with an effective date of the first quarter of fiscal 2022. The Company is currently assessing the impact of the adoption of this standard on its consolidated financial statements and employee benefit plans’ accounting.

In August 2016, FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. ASU 2016-15 eliminates the diversity in practice related to the classification of certain cash receipts and payments for debt prepayment or extinguishment costs, the maturing of a zero coupon bond, the settlement of contingent liabilities arising from a business combination, proceeds from insurance settlements, distributions from certain equity method investees and beneficial interests obtained in a financial asset securitization. ASU 2016-15 designates the appropriate cash flow classification, including requirements to allocate certain components of these cash receipts and payments among operating, investing and financing activities. The retrospective transition method, requiring adjustment to all comparative periods presented, is required unless it is impracticable for some of the amendments, in which case those amendments would be prospectively adjusted as of the earliest date practicable. The standard is effective on January 1, 2019. The Company is currently assessing the impact of the adoption of this standard on its consolidated financial statements.

Short-Term Investments
Short-Term Investments

NOTE 2: SHORT-TERM INVESTMENTS

The Company invests in marketable U.S. Treasury Bills (“T-bills”) that are classified as held-to-maturity securities. The amortized cost and recorded basis of the T-bills are presented as short-term investments in the amount of $119,724 and $150,001 as of September 30, 2016 and December 31, 2015, respectively, and their estimated fair value as of September 30, 2016 and December 31, 2015 was $119,604 and $149,978, respectively.

Inventories
Inventories

NOTE 3: INVENTORIES

Inventories are stated at the lower of cost or market. The weighted average methodology is applied to determine cost. As of September 30, 2016 and December 31, 2015, the Company’s inventories were composed of:

 

 

 

September 30,

 

 

December 31,

 

 

 

2016

 

 

2015

 

 

 

Unaudited

 

 

Audited

 

Raw materials

 

$

4,517

 

 

$

3,518

 

Work in progress

 

 

9,621

 

 

 

4,618

 

Finished products

 

 

9,834

 

 

 

5,458

 

Total

 

$

23,972

 

 

$

13,594

 

 

Commitments and Contingent Liabilities
Commitments and Contingent Liabilities

NOTE 4: COMMITMENTS AND CONTINGENT LIABILITIES

The facilities of the Company are leased under various operating lease agreements for periods ending no later than 2024. The Company also leases motor vehicles under various operating leases, which expire on various dates, the latest of which is in 2019.

As of September 30, 2016 and December 31, 2015, the Company pledged bank deposits of $807 and $133, respectively, to cover bank guarantees in respect of its leases of operating facilities and obtained guarantees by the bank for the fulfillment of the Company’s lease commitments of $962 and $283, respectively.

Share Capital
Share Capital

NOTE 5: SHARE CAPITAL

For the nine months ended September 30, 2016, warrants to purchase 220,316 ordinary shares with an exercise price of $3.59 were exercised, resulting in the issuance of 220,316 ordinary shares, and warrants to purchase 975,644 and 888,219 ordinary shares with exercise prices of $18.09 and $3.59 per share, respectively, were cashlessly exercised, resulting in the issuance of 950,637 ordinary shares. For the nine months ended September 30, 2016, options to purchase 825,240 ordinary shares were exercised for cash and options to purchase 3,547 ordinary shares were cashlessly exercised, resulting in the issuance of 825,669 ordinary shares.  For additional information on option exercises, please see Note 6.

Equity Incentive Plan
Equity Incentive Plan

NOTE 6: EQUITY INCENTIVE PLAN

In September 2015, the Company adopted the 2015 Omnibus Incentive Plan (the “2015 Plan”). The 2015 Plan replaced the 2013 Share Option Plan.  Under the 2015 Plan, the Company can issue various types of equity compensation awards such as restricted shares, performance shares, restricted stock units, performance units, long-term cash award and other share-based awards.  

The options granted under the 2015 Plan generally have a four-year vesting period and expire ten years after the date of grant. Options granted under the 2015 Plan that are cancelled or forfeited before expiration become available for future grant.

As of September 30, 2016, 12,717,460 ordinary shares were available for grant under the 2015 Plan.  

A summary of the status of the Company’s option plans as of September 30, 2016 and changes during the period then ended is presented below: 

 

 

 

Nine months ended September 30,

 

 

 

Unaudited

 

 

 

Number

of options

 

 

Weighted

average

exercise

price

 

Outstanding at beginning of year

 

 

10,134,829

 

 

$

8.20

 

Granted

 

 

2,363,575

 

 

 

13.61

 

Exercised

 

 

(828,787

)

 

 

0.24

 

Forfeited and cancelled

 

 

(133,364

)

 

 

17.19

 

 

 

 

 

 

 

 

 

 

Outstanding as of September 30, 2016

 

 

11,536,253

 

 

 

9.78

 

 

 

 

 

 

 

 

 

 

Exercisable options

 

 

5,887,411

 

 

 

5.05

 

 

 

 

 

 

 

 

 

 

Vested and expected to vest

 

 

11,329,415

 

 

$

9.71

 

 

In September 2015, the Company adopted an employee share purchase plan (“ESPP”) to encourage and enable eligible employees to acquire ownership of the Company’s ordinary shares purchased through accumulated payroll deductions on an after-tax basis. In the United States, the ESPP is intended to be an “employee stock purchase plan” within the meaning of Section 423 of the Internal Revenue Code and the provisions of the ESPP will be construed in a manner consistent with the requirements of such section. The Company began its offerings under the ESPP on August 1, 2016.  As of September 30, 2016, 1,667,785 ordinary shares were available to be purchased by eligible employees under the ESPP and no shares had been issued under the ESPP.

The fair value of equity-based awards was estimated using the Black-Scholes option-pricing model for all grants with the following underlying assumptions: 

 

 

 

Nine months ended September 30,

 

 

Year ended

December 31,

 

 

2016

 

 

2015

 

 

2015

 

 

Unaudited

 

 

Audited

Stock Option Plans

 

 

 

 

 

 

 

 

 

 

Expected term (years)

 

6.25

 

 

 

6.25

 

 

6.25

Expected volatility

 

59.12%-61.65%

 

 

62.50% - 65.80%

 

 

59.00%-65.80%

Risk-free interest rate

 

1.23%-1.88%

 

 

1.75% - 1.90%

 

 

1.74%-2.05%

Dividend yield

 

0%

 

 

0%

 

 

0%

ESPP

 

 

 

 

 

 

 

 

 

 

Expected term (years)

 

0.42

 

 

-

 

 

-

Expected volatility

 

 

70.45

%

 

-

 

 

-

Risk-free interest rate

 

 

0.40

%

 

-

 

 

-

Dividend yield

 

0%

 

 

-

 

 

-

 

The total non-cash share-based compensation expense related to all of the Company’s equity-based awards recognized for the three and nine months ended September 30, 2016 and 2015 and the year ended December 31, 2015 was:

 

 

 

Three months ended September 30,

 

 

Nine months ended September 30,

 

 

Year ended

December 31,

 

 

 

2016

 

 

2015

 

 

2016

 

 

2015

 

 

2015

 

 

 

Unaudited

 

 

Unaudited

 

 

Audited

 

Cost of revenues

 

$

160

 

 

$

35

 

 

$

471

 

 

$

54

 

 

$

174

 

Research, development and clinical

   trials

 

 

776

 

 

 

668

 

 

 

2,378

 

 

 

1,717

 

 

 

2,529

 

Sales and marketing

 

 

1,249

 

 

 

571

 

 

 

3,888

 

 

 

1,550

 

 

 

2,496

 

General and administrative

 

 

3,441

 

 

 

1,654

 

 

 

9,982

 

 

 

4,051

 

 

 

6,661

 

Total share-based compensation

   expense

 

$

5,626

 

 

$

2,928

 

 

$

16,719

 

 

$

7,372

 

 

$

11,860

 

 

Supplemental Information
Supplemental Information

NOTE 7: SUPPLEMENTAL INFORMATION

The Company operates in a single reportable segment.

The following table presents long-lived assets by location:

 

 

 

September 30,

 

 

December 31,

 

 

 

2016

 

 

2015

 

 

 

Unaudited

 

 

Audited

 

United States

 

$

11,792

 

 

$

6,600

 

Switzerland

 

 

3,769

 

 

 

4,204

 

Israel

 

 

1,934

 

 

 

1,376

 

Others

 

 

433

 

 

 

401

 

Total

 

$

17,928

 

 

$

12,581

 

 

The Company’s revenues by geographic region, based on the customer’s location, are summarized as follows:

 

 

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

 

Year ended December 31,

 

 

 

2016

 

 

2015

 

 

2016

 

 

2015

 

 

2015

 

 

 

Unaudited

 

 

Unaudited

 

 

Audited

 

United States

 

$

18,131

 

 

$

8,546

 

 

$

46,264

 

 

$

19,710

 

 

$

30,961

 

EMEA

 

 

3,519

 

 

 

407

 

 

 

6,296

 

 

 

994

 

 

 

2,070

 

Japan

 

 

24

 

 

 

-

 

 

 

86

 

 

 

-

 

 

 

56

 

Total

 

$

21,674

 

 

$

8,953

 

 

$

52,646

 

 

$

20,704

 

 

$

33,087

 

 

Long-Term Loan, Net of Discount and Issuance Costs
Long-Term Loan, Net of Discount and Issuance Costs

NOTE 8: LONG-TERM LOAN, NET OF DISCOUNT AND ISSUANCE COSTS

In January 2015, the Company entered into a five-year term loan agreement (the “Term Loan Credit Facility”) with a lender to draw up to $100,000. In January 2015, the Company drew $25,000 from the lender. The Company had the option to draw the remaining $75,000 at its option at any time through June 30, 2016. On June 30, 2016, the Company provided to the lender a drawdown notice for the remaining $75,000, and it received funds in July 2016. As of September 30, 2016, there is $100,000 outstanding under the Term Loan Credit Facility.

Interest on the outstanding loan is 10% annually, payable quarterly in arrears. In addition, there is a 1.5% funding fee payable on the amount drawn on the funding date, a 0.75% pay-down fee on all principal amount repayments to be paid on the date such payments of principal are made and a pre-payment fee of 3.0%, 2.0% or 1.0% if the Company prepays outstanding loan amounts prior to the first, second or third year anniversaries, respectively, from the initial funding date. The entire outstanding principal loan is due in January 2020. The loan is secured by a first priority security interest in substantially all assets of the Company. The Term Loan Credit Facility sets forth certain affirmative and negative covenants with which the Company must comply on a quarterly basis through the term of the loan. As of September 30, 2016, the Company was in compliance with such covenants.

The total discount of $2,019 and additional issuance costs of $2,744 are presented net of the loan and are amortized to interest expense over the term of the loan using the effective interest method.

Impairment of Field Equipment
Impairment of Field Equipment

NOTE 9: IMPAIRMENT OF FIELD EQUIPMENT

 

The Company received U.S. Food and Drug Administration approval on its Premarket Approval supplement application to market its second generation Optune System in the United States on July 13, 2016. The Company made the second generation Optune System available to all patients in the United States during the quarter ended September 30, 2016.  Manufacturing of the first generation Optune System has been terminated. For the nine months ended September 30, 2016, the Company recorded an impairment loss in the second quarter with respect to the write-off of first generation Optune System field equipment (finished goods and production stage) in the amount of $6,412, including advances for materials purchased and liabilities incurred to vendors of $1,582 that are not recoverable, presented in cost of revenues. The Company does not expect the conversion to result in an additional material impairment charge in the future.  

Organization and Basis of Presentation (Policies)
Recently Issued Accounting Pronouncement

Recently Issued Accounting Pronouncements. In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-02-Leases (ASC 842), which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e. lessees and lessors). The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight line basis over the term of the lease, respectively. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than twelve months regardless of their classification. Leases with a term of twelve months or less will be accounted for similar to existing guidance for operating leases. The new standard requires lessors to account for leases using an approach that is substantially equivalent to existing guidance for sales-type leases, direct financing leases and operating leases. ASC 842 supersedes the previous leases standard, ASC 840. The standard is effective on January 1, 2019, with early adoption permitted. The Company is currently evaluating the impact of the adoption of this standard on its consolidated financial statements.

In March 2016, FASB issued ASU 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The amendments in ASU 2016-09 affect all entities that issue share-based payment awards to their employees and involve multiple aspects of the accounting for share-based payment transactions, including income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. ASU 2016-09 is effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. Early adoption is permitted in any interim or annual period. The Company is currently evaluating the impact of the adoption of this standard on its consolidated financial statements.

In April 2016, FASB issued ASU 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing. ASU 2016-10 covers two specific topics: performance obligations and licensing. This amendment includes guidance on immaterial promised goods or services, shipping or handling activities, separately identifiable performance obligations, functional or symbolic intellectual property licenses, sales-based and usage-based royalties, license restrictions (time, use, geographical) and licensing renewals. In addition, in May 2016, FASB issued ASU No. 2016-12, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients, which is intended to not change the core principle of the guidance in Topic 606, but rather affect only the narrow aspects of Topic 606 by reducing the potential for diversity in practice at initial application and by reducing the cost and complexity of applying Topic 606 both at transition and on an ongoing basis. The Company is currently evaluating the impact of the adoption of both revenue standards on its consolidated financial statements.

In June 2016, FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. ASU 2016-13 amends the impairment model to utilize an expected loss methodology in place of the currently used incurred loss methodology, which will result in the more timely recognition of losses. ASU 2016-13 also applies to employee benefit plan accounting, with an effective date of the first quarter of fiscal 2022. The Company is currently assessing the impact of the adoption of this standard on its consolidated financial statements and employee benefit plans’ accounting.

In August 2016, FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. ASU 2016-15 eliminates the diversity in practice related to the classification of certain cash receipts and payments for debt prepayment or extinguishment costs, the maturing of a zero coupon bond, the settlement of contingent liabilities arising from a business combination, proceeds from insurance settlements, distributions from certain equity method investees and beneficial interests obtained in a financial asset securitization. ASU 2016-15 designates the appropriate cash flow classification, including requirements to allocate certain components of these cash receipts and payments among operating, investing and financing activities. The retrospective transition method, requiring adjustment to all comparative periods presented, is required unless it is impracticable for some of the amendments, in which case those amendments would be prospectively adjusted as of the earliest date practicable. The standard is effective on January 1, 2019. The Company is currently assessing the impact of the adoption of this standard on its consolidated financial statements.

Inventories (Tables)
Schedule of Inventories

Inventories are stated at the lower of cost or market. The weighted average methodology is applied to determine cost. As of September 30, 2016 and December 31, 2015, the Company’s inventories were composed of:

 

 

 

September 30,

 

 

December 31,

 

 

 

2016

 

 

2015

 

 

 

Unaudited

 

 

Audited

 

Raw materials

 

$

4,517

 

 

$

3,518

 

Work in progress

 

 

9,621

 

 

 

4,618

 

Finished products

 

 

9,834

 

 

 

5,458

 

Total

 

$

23,972

 

 

$

13,594

 

 

Equity Incentive Plan (Tables)

A summary of the status of the Company’s option plans as of September 30, 2016 and changes during the period then ended is presented below: 

 

 

 

Nine months ended September 30,

 

 

 

Unaudited

 

 

 

Number

of options

 

 

Weighted

average

exercise

price

 

Outstanding at beginning of year

 

 

10,134,829

 

 

$

8.20

 

Granted

 

 

2,363,575

 

 

 

13.61

 

Exercised

 

 

(828,787

)

 

 

0.24

 

Forfeited and cancelled

 

 

(133,364

)

 

 

17.19

 

 

 

 

 

 

 

 

 

 

Outstanding as of September 30, 2016

 

 

11,536,253

 

 

 

9.78

 

 

 

 

 

 

 

 

 

 

Exercisable options

 

 

5,887,411

 

 

 

5.05

 

 

 

 

 

 

 

 

 

 

Vested and expected to vest

 

 

11,329,415

 

 

$

9.71

 

 

The fair value of equity-based awards was estimated using the Black-Scholes option-pricing model for all grants with the following underlying assumptions: 

 

 

 

Nine months ended September 30,

 

 

Year ended

December 31,

 

 

2016

 

 

2015

 

 

2015

 

 

Unaudited

 

 

Audited

Stock Option Plans

 

 

 

 

 

 

 

 

 

 

Expected term (years)

 

6.25

 

 

 

6.25

 

 

6.25

Expected volatility

 

59.12%-61.65%

 

 

62.50% - 65.80%

 

 

59.00%-65.80%

Risk-free interest rate

 

1.23%-1.88%

 

 

1.75% - 1.90%

 

 

1.74%-2.05%

Dividend yield

 

0%

 

 

0%

 

 

0%

ESPP

 

 

 

 

 

 

 

 

 

 

Expected term (years)

 

0.42

 

 

-

 

 

-

Expected volatility

 

 

70.45

%

 

-

 

 

-

Risk-free interest rate

 

 

0.40

%

 

-

 

 

-

Dividend yield

 

0%

 

 

-

 

 

-

 

The total non-cash share-based compensation expense related to all of the Company’s equity-based awards recognized for the three and nine months ended September 30, 2016 and 2015 and the year ended December 31, 2015 was:

 

 

 

Three months ended September 30,

 

 

Nine months ended September 30,

 

 

Year ended

December 31,

 

 

 

2016

 

 

2015

 

 

2016

 

 

2015

 

 

2015

 

 

 

Unaudited

 

 

Unaudited

 

 

Audited

 

Cost of revenues

 

$

160

 

 

$

35

 

 

$

471

 

 

$

54

 

 

$

174

 

Research, development and clinical

   trials

 

 

776

 

 

 

668

 

 

 

2,378

 

 

 

1,717

 

 

 

2,529

 

Sales and marketing

 

 

1,249

 

 

 

571

 

 

 

3,888

 

 

 

1,550

 

 

 

2,496

 

General and administrative

 

 

3,441

 

 

 

1,654

 

 

 

9,982

 

 

 

4,051

 

 

 

6,661

 

Total share-based compensation

   expense

 

$

5,626

 

 

$

2,928

 

 

$

16,719

 

 

$

7,372

 

 

$

11,860

 

 

Supplemental Information (Tables)

The following table presents long-lived assets by location:

 

 

 

September 30,

 

 

December 31,

 

 

 

2016

 

 

2015

 

 

 

Unaudited

 

 

Audited

 

United States

 

$

11,792

 

 

$

6,600

 

Switzerland

 

 

3,769

 

 

 

4,204

 

Israel

 

 

1,934

 

 

 

1,376

 

Others

 

 

433

 

 

 

401

 

Total

 

$

17,928

 

 

$

12,581

 

 

The Company’s revenues by geographic region, based on the customer’s location, are summarized as follows:

 

 

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

 

Year ended December 31,

 

 

 

2016

 

 

2015

 

 

2016

 

 

2015

 

 

2015

 

 

 

Unaudited

 

 

Unaudited

 

 

Audited

 

United States

 

$

18,131

 

 

$

8,546

 

 

$

46,264

 

 

$

19,710

 

 

$

30,961

 

EMEA

 

 

3,519

 

 

 

407

 

 

 

6,296

 

 

 

994

 

 

 

2,070

 

Japan

 

 

24

 

 

 

-

 

 

 

86

 

 

 

-

 

 

 

56

 

Total

 

$

21,674

 

 

$

8,953

 

 

$

52,646

 

 

$

20,704

 

 

$

33,087

 

 

Short-Term Investments - Additional Information (Details) (USD $)
In Thousands, unless otherwise specified
Sep. 30, 2016
Dec. 31, 2015
Investments Debt And Equity Securities [Abstract]
 
 
Short-term investments
$ 119,724 
$ 150,001 
Estimated fair value of short-term investments
$ 119,604 
$ 149,978 
Inventories - Schedule of Inventories (Details) (USD $)
In Thousands, unless otherwise specified
Sep. 30, 2016
Dec. 31, 2015
Inventory Disclosure [Abstract]
 
 
Raw materials
$ 4,517 
$ 3,518 
Work in progress
9,621 
4,618 
Finished products
9,834 
5,458 
Total
$ 23,972 
$ 13,594 
Commitments and Contingent Liabilities - Additional Information (Details) (USD $)
In Thousands, unless otherwise specified
9 Months Ended
Sep. 30, 2016
Dec. 31, 2015
Loss Contingencies [Line Items]
 
 
Operating lease expiration description
The facilities of the Company are leased under various operating lease agreements for periods ending no later than 2024. 
 
Pledged bank deposits
$ 807 
$ 133 
Operating Lease Commitments
$ 962 
$ 283 
Motor Vehicles
 
 
Loss Contingencies [Line Items]
 
 
Operating lease expiration description
The Company also leases motor vehicles under various operating leases, which expire on various dates, the latest of which is in 2019. 
 
Maximum
 
 
Loss Contingencies [Line Items]
 
 
Operating lease agreements, expiration year
2024 
 
Maximum |
Motor Vehicles
 
 
Loss Contingencies [Line Items]
 
 
Operating lease agreements, expiration year
2019 
 
Share Capital - Additional Information (Details) (USD $)
9 Months Ended
Sep. 30, 2016
Share Capital [Line Items]
 
Options issued to purchase ordinary shares exercised for cash
825,240 
Options issued to purchase ordinary shares cashlessly exercised
3,547 
Ordinary shares issued upon option exercise
825,669 
Warrants to Purchase 220,316 Ordinary Shares
 
Share Capital [Line Items]
 
Warrants issued to purchase of ordinary shares
220,316 
Warrants exercise price
$ 3.59 
Warrants exercised to ordinary shares
220,316 
Warrants to Purchase 975,644 Ordinary Shares
 
Share Capital [Line Items]
 
Warrants issued to purchase of ordinary shares
975,644 
Warrants exercise price
$ 18.09 
Warrants to Purchase 888,219 Ordinary Shares
 
Share Capital [Line Items]
 
Warrants issued to purchase of ordinary shares
888,219 
Warrants exercise price
$ 3.59 
Warrant
 
Share Capital [Line Items]
 
Warrants exercised to ordinary shares
950,637 
Equity Incentive Plan - Additional Information (Details)
9 Months Ended
Sep. 30, 2016
ESPP
 
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
 
Ordinary shares available for grants
1,667,785 
Shares issued under plan
2015 Plan
 
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
 
Option granted vesting period
4 years 
Option granted expiration period
10 years 
Ordinary shares available for grants
12,717,460 
Equity Incentive Plan - Schedule of Stock Option Plan (Details) (USD $)
9 Months Ended
Sep. 30, 2016
Number of options
 
Number of options, Outstanding at beginning of year
10,134,829 
Number of options, Granted
2,363,575 
Number of options, Exercised
(828,787)
Number of options, Forfeited and cancelled
(133,364)
Number of options, Outstanding at ending of year
11,536,253 
Number of options, Exercisable options
5,887,411 
Number of options, Vested and expected to vest
11,329,415 
Weighted average exercise price
 
Weighted average exercise price, Outstanding at beginning of year
$ 8.20 
Weighted average exercise price, Granted
$ 13.61 
Weighted average exercise price, Exercised
$ 0.24 
Weighted average exercise price, Forfeited and cancelled
$ 17.19 
Weighted average exercise price, Outstanding at end of year
$ 9.78 
Weighted average exercise price, Exercisable options
$ 5.05 
Weighted average exercise price, Vested and expected to vest
$ 9.71 
Equity Incentive Plan - Schedule of Fair Value of Equity Based Awards Using Black-Scholes Option Pricing Model (Details)
9 Months Ended 12 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Dec. 31, 2015
Stock Option Plans
 
 
 
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
 
 
 
Expected term (years)
6 years 3 months 
6 years 3 months 
6 years 3 months 
Expected volatility, minimum
59.12% 
62.50% 
59.00% 
Expected volatility, maximum
61.65% 
65.80% 
65.80% 
Risk-free interest rate, minimum
1.23% 
1.75% 
1.74% 
Risk-free interest rate, maximum
1.88% 
1.90% 
2.05% 
Dividend yield
0.00% 
0.00% 
0.00% 
ESPP
 
 
 
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
 
 
 
Expected term (years)
5 months 
 
 
Dividend yield
0.00% 
 
 
Expected volatility
70.45% 
 
 
Risk-free interest rate
0.40% 
 
 
Supplemental Information - Schedule of Long-Lived Assets by Location (Details) (USD $)
In Thousands, unless otherwise specified
Sep. 30, 2016
Dec. 31, 2015
Revenues From External Customers And Long Lived Assets [Line Items]
 
 
Long-lived assets
$ 17,928 
$ 12,581 
United States
 
 
Revenues From External Customers And Long Lived Assets [Line Items]
 
 
Long-lived assets
11,792 
6,600 
Switzerland
 
 
Revenues From External Customers And Long Lived Assets [Line Items]
 
 
Long-lived assets
3,769 
4,204 
Israel
 
 
Revenues From External Customers And Long Lived Assets [Line Items]
 
 
Long-lived assets
1,934 
1,376 
Others
 
 
Revenues From External Customers And Long Lived Assets [Line Items]
 
 
Long-lived assets
$ 433 
$ 401 
Supplemental Information - Schedule of Revenues by Geographic Region (Details) (USD $)
In Thousands, unless otherwise specified
3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Dec. 31, 2015
Revenues From External Customers And Long Lived Assets [Line Items]
 
 
 
 
 
Net revenues
$ 21,674 
$ 8,953 
$ 52,646 
$ 20,704 
$ 33,087 
United States
 
 
 
 
 
Revenues From External Customers And Long Lived Assets [Line Items]
 
 
 
 
 
Net revenues
18,131 
8,546 
46,264 
19,710 
30,961 
EMEA
 
 
 
 
 
Revenues From External Customers And Long Lived Assets [Line Items]
 
 
 
 
 
Net revenues
3,519 
407 
6,296 
994 
2,070 
Japan
 
 
 
 
 
Revenues From External Customers And Long Lived Assets [Line Items]
 
 
 
 
 
Net revenues
$ 24 
 
$ 86 
 
$ 56 
Long-Term Loan, Net of Discount and Issuance Costs - Additional Information (Details) (Term Loan, USD $)
1 Months Ended 9 Months Ended
Jan. 31, 2015
Sep. 30, 2016
Jun. 30, 2016
Line Of Credit Facility [Line Items]
 
 
 
Term loan agreement, maturity period
5 years 
 
 
Line of credit facility, maximum borrowing capacity
$ 100,000,000 
 
 
Line of credit facility, current borrowing capacity
25,000,000 
 
 
Line of credit facility, remaining borrowing capacity
 
 
75,000,000 
Line of credit facility, drawdown received date
 
2016-07 
 
Term loan credit facility, outstanding
 
100,000,000 
 
Interest on the outstanding loan
 
10.00% 
 
Funding fees payable
 
1.50% 
 
Prepayment fee percent
 
0.75% 
 
Due date of outstanding principal loan
 
Jan. 31, 2020 
 
Frequency of payments
 
Quarterly 
 
Other Long-term Assets
 
 
 
Line Of Credit Facility [Line Items]
 
 
 
Total discount
 
2,019,000 
 
Additional deferred issuance costs
 
$ 2,744,000 
 
First Year
 
 
 
Line Of Credit Facility [Line Items]
 
 
 
Prepayment fee percent
 
3.00% 
 
Second Year
 
 
 
Line Of Credit Facility [Line Items]
 
 
 
Prepayment fee percent
 
2.00% 
 
Third Year
 
 
 
Line Of Credit Facility [Line Items]
 
 
 
Prepayment fee percent
 
1.00% 
 
Impairment of Field Equipment - Additional Information (Details) (USD $)
In Thousands, unless otherwise specified
9 Months Ended
Sep. 30, 2016
Impaired Long Lived Assets Held And Used [Line Items]
 
Impairment of field equipment
$ 6,412 
First Generation Optune System Field Equipment |
Cost of Revenues
 
Impaired Long Lived Assets Held And Used [Line Items]
 
Impairment of field equipment
6,412 
Advances for materials purchased and liabilities incurred to vendors
$ 1,582